Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth has reached a deal with drug makers Ely Lilly and Novo Nordisk which it said will bring prices down for employers and their workers."This solution is really focused towards clients that aren't covering it today, and what it allows us to do is one, to bring it on at a reduced price for the plan sponsor, but also cap ...

Regeneron buys 23andMe Getty ImagesRegeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitive customer DNA information.According to Reuters, the New York-based pharmaceutical giant aims to leverage 23andMe’s extensive database of over 15 million customer DNA samples to enhance its genomic-driven drug discovery processes. The acquisition comes at a crucial time as con ...

Sign with logo at entrance to office of aerospace company Boeing. (Photo by Smith ... More Collection/Gado/Getty Images)Getty ImagesThe past several weeks have been a welcome change for Boeing, which has struggled for the past seven years with fatal crashes, a pandemic travel shutdown, quality and safety incidents halting production and a labor strike that pushed the company to the brink.However, after nine months on the job, CEO Kelly Ortberg’s recovery plan is showing strong progress.On April 22, Boeing a ...

Nike shoes are seen in the King of Prussia Mall, as global markets brace for a hit to trade and growth caused by U.S. President Donald Trump's decision to impose import tariffs on dozens of countries, in King of Prussia, Pennsylvania, U.S., April 3, 2025.Nike will raise prices on a wide range of footwear, apparel and equipment as soon as this week as the retail industry braces for tariffs to hit its profits, CNBC has learned.Prices for Nike apparel and equipment for adults will increase between $2 and $10, ...

BROOMFIELD, Colo., May 21, 2025 /PRNewswire/ -- Crocs, Inc. (NASDAQ: CROX), a world leader in innovative casual footwear for all, today announced that the organization has elevated Terence Reilly to Executive Vice President, Chief Brand Officer, with oversight over the marketing and communications functions for both the Crocs and HEYDUDE brands, effective immediately.As a veteran brand expert, Terence has a proven track record of building lasting brand identity, connecting to relevant culture and creating s ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participati ...

Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patientsST LOUIS, May 21, 2025  /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss me ...

SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The ...

Core Insights - Eli Lilly and Company has received marketing authorization for Kisunla (donanemab) in Australia, marking it as the first amyloid-targeting therapy for Alzheimer's registered in the country [1][3] - Kisunla is indicated for adult patients with mild cognitive impairment and mild dementia due to Alzheimer's disease, specifically targeting Apolipoprotein E ε4 heterozygotes or non-carriers [1][6] - The drug has shown significant efficacy in slowing cognitive and functional decline in early symptomatic Alzheimer's disease, with a 35% reduction in decline compared to placebo over 18 months [3][9] Regulatory and Clinical Data - The authorization in Australia is based on data from the TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 clinical trials, which demonstrated the drug's effectiveness and safety profile [3][4] - Kisunla has been approved in multiple countries, including the United States, Japan, and the United Kingdom, totaling 13 regulatory authorizations [5][10] - The TRAILBLAZER-ALZ 2 study involved 1,736 participants and showed a 39% reduced risk of progressing to the next clinical stage of Alzheimer's disease [3][7] Patient Population and Impact - Approximately 600,000 Australians are living with Alzheimer's disease, with around 450,000 in early stages eligible for Kisunla treatment [3][4] - Alzheimer's disease is the third leading cause of death in Australia, highlighting the urgent need for effective treatments [3][4] - The earlier patients are diagnosed and treated with Kisunla, the better their response to the therapy, emphasizing the importance of timely intervention [3][10] Safety and Side Effects - Kisunla can cause amyloid-related imaging abnormalities (ARIA), which are generally asymptomatic but can lead to serious complications [4][12] - A modified titration schedule has been approved to reduce the incidence of ARIA while maintaining the drug's efficacy [4][9] - The product information includes warnings about potential serious side effects, including infusion-related reactions and ARIA [12][16]

Core Viewpoint - Lowe's reported a smaller-than-expected decline in first-quarter sales and plans to maintain competitive pricing, while not ruling out potential price increases due to tariffs [1][5][12] Sales Performance - The company experienced a 1.7% drop in same-store sales for the quarter ended May 2, which was better than analysts' average estimate of a 2% decline [12] - Steady demand from construction professionals contributed to the smaller-than-expected sales drop [6] Pricing Strategy - CEO Marvin Ellison emphasized the importance of competitive pricing to avoid losing market share to competitors [1] - CFO Brandon Sink indicated that profit margins are expected to remain flat this fiscal year, with tariff impacts anticipated in the second half of the year [2] Tariff Impact - The imposition of tariffs has raised concerns in the retail sector, with Walmart warning of potential price increases and Target lowering its sales and profit forecasts [3] - Lowe's and Home Depot have both been affected by tariff fears, which have negatively impacted consumer sentiment and renovation projects [4][8] Supply Chain Management - Lowe's has diversified its supply chain and increased local suppliers to mitigate the impact of U.S. tariffs [7] - Approximately 60% of Lowe's purchase volume comes from the U.S., while 20% is sourced from China, with specific items like holiday trees and tools being affected by tariffs [10] Future Outlook - The company expects comparable sales for 2025 to be flat to 1% higher, with earnings per share projected between $12.15 and $12.40 [11]